Niels Andreasen

发表

Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease

Eric Westman, Kaj Blennow, Per Almqvist, 2015, Alzheimer's & Dementia.

Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease

Kaj Blennow, Lennart Minthon, K. Blennow, 2001, Neuroscience Letters.

Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease.

Kaj Blennow, Carol L Nilsson, K. Blennow, 2003, Brain research. Molecular brain research.

Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.

Katharina Buerger, Frank Padberg, Harald Hampel, 2002, Archives of neurology.

Cerebrospinal fluid τ and β-amyloid(1-42) in dementia disorders

Kaj Blennow, Hugo Vanderstichele, Lennart Minthon, 2001, Mechanisms of Ageing and Development.

Encapsulated Cell Biodelivery of Nerve Growth Factor to the Basal Forebrain in Patients with Alzheimer’s Disease

Ove Almkvist, Kaj Blennow, Vesna Jelic, 2012, Dementia and Geriatric Cognitive Disorders.

Measurement of Apolipoprotein E (apoE) in Cerebrospinal Fluid

Kaj Blennow, Lennart Minthon, Pam Fredman, 2000, Neurochemical Research.

Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment.

Anders Wallin, Annika Olsson, Kaj Blennow, 2005, Clinical chemistry.

Determinants of costs of care for patients with Alzheimer's disease

Gunhild Waldemar, Hilkka Soininen, Linus Jönsson, 2006, International journal of geriatric psychiatry.

Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease

Henrik Zetterberg, Kaj Blennow, Oskar Hansson, 2009, PloS one.

Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients.

Anders Wallin, Henrik Zetterberg, Kaj Blennow, 2009, Journal of Alzheimer's disease : JAD.

Plasma levels of 24S-hydroxycholesterol reflect brain volumes in patients without objective cognitive impairment but not in those with Alzheimer's disease

Ariadna Besga, Hilkka Soininen, Miia Kivipelto, 2009, Neuroscience Letters.

Amino-Truncated β-Amyloid42 Peptides in Cerebrospinal Fluid and Prediction of Progression of Mild Cognitive Impairment

Anders Wallin, Annika Olsson, Kaj Blennow, 2005 .

Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.

Katharina Buerger, Harald Hampel, Kaj Blennow, 2004, Archives of general psychiatry.

Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients

Kaj Blennow, Carol L Nilsson, Ann Westman-Brinkmalm, 2002, Neuroreport.

Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study

Alberto Russu, Sebastiaan Engelborghs, S. Engelborghs, 2018, Alzheimer's Research & Therapy.

Towards compendia of negative genetic association studies: an example for Alzheimer disease

Kaj Blennow, Lars Feuk, L. Feuk, 2006, Human Genetics.

Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment

Giovanni B. Frisoni, Gunhild Waldemar, Juha O. Rinne, 2017, Alzheimer's & Dementia.

Patient- and Proxy-Reported Utility in Alzheimer Disease Using the EuroQoL

Gunhild Waldemar, Hilkka Soininen, Linus Jönsson, 2006, Alzheimer disease and associated disorders.

Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers

Hilkka Soininen, Kaj Blennow, Michael Flory, 2005, Annals of neurology.

Cerebrospinal fluid levels of total‐tau, phospho‐tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairment

Kaj Blennow, Hugo Vanderstichele, Eugeen Vanmechelen, 2003 .

Ratio of Aβ42/P-tau181p in CSF is associated with aberrant default mode network in AD

Eric Westman, Tie-Qiang Li, Lars-Olof Wahlund, 2013, Scientific Reports.

An Alzheimer's disease-specific β-amyloid fragment signature in cerebrospinal fluid

Anders Wallin, Henrik Zetterberg, Kaj Blennow, 2006, Neuroscience Letters.

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases

Magda Tsolaki, José Luis Molinuevo, Enrica Cavedo, 2015, Nature Reviews Neurology.

The cost of diagnosing dementia in a community setting

Linus Jönsson, Anders Wimo, J. Strömqvist, 2010, International journal of geriatric psychiatry.

Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

Anders Wallin, Björn Holmberg, Annika Olsson, 2005, Clinical chemistry.

Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial.

John Seibyl, Vladimir Coric, Hilkka Soininen, 2015, JAMA neurology.

Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.

Kaj Blennow, Hugo Vanderstichele, Eugeen Vanmechelen, 2003, Acta neurologica Scandinavica. Supplementum.

Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer’s disease patients: application of a second-generation encapsulated cell biodelivery device

Eric Westman, Ove Almkvist, Kaj Blennow, 2016, Alzheimer's Research & Therapy.

β-Amyloid (Aβ) protein in cerebrospinal fluid as a biomarker for Alzheimer’s disease

Kaj Blennow, K. Blennow, N. Andreasen, 2002, Peptides.